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Parkinson’s disease (PD) and Multiple System Atrophy (MSA) are progressive
neurodegenerative diseases with overlap of symptoms in early stages of disease.
No reliable biomarker exists and the diagnosis is mainly based on clinical features.
Several studies suggest that miRNAs are involved in PD and MSA pathogenesis. Our
goal was to study two serum circulating microRNAs (miR-96-5p and miR-339-5p) as
novel biomarkers for the differential diagnosis between PD and MSA. Serum samples
were obtained from 51 PD patients, 52 MSA patients and 56 healthy controls (HC).
We measured levels of miRNAs using quantitative PCR and compared the levels of
miR-96-5p and miR-339-5p among PD, MSA and HC groups using a one-way analysis
of variance. Correlations between miRNA expression and clinical data were calculated
using Pearson’s rho test. We used the miRTarBase to detect miRNA targets and STRING
to evaluate co-expression relationship among target genes. MiR-96-5p was significantly
increased in MSA patients compared with HC (Fold change (fc): 3.6; p = 0.0001) while
it was decreased in PD patients compared with HC (Fold change: 4; p = 0.0002).
Higher miR-96-5P levels were directly related to longer disease duration in MSA patients.
We observed a significant increase of miR-339-5p in MSA patients compared with PD
patients (fc: 2.5; p = 0.00013). miR-339-5p was increased in MSA patients compared
with HC (fc: 2.4; p= 0.002). We identified 32 target genes of miR-96-5p andmiR-339-5p,
some of which are involved in neurodegenerative diseases. The study of those miRNAs
could be useful to identify non-invasive biomarkers for early differential diagnosis between
PD and MSA.
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INTRODUCTION
Parkinson’s disease (PD) and Multiple System Atrophy (MSA)
are neurodegenerative disorders with overlap of symptoms,
especially at early disease stages. However, they present different
disease progression and response to dopaminergic treatment
(Vallelunga et al., 2014a). The diagnosis is mostly based on
clinical features while no serum biomarker is currently available
(Laurens et al., 2015). Several reports support the hypothesis
of overlapping molecular pathways between Alzheimer’s disease
(AD) and both MSA and PD. Many studies reported significant
associations among detectable changes in cerebrospinal fluid
(CSF), amyloid beta (Aβ) levels and clinical features of PD
(Beyer et al., 2013; Kang et al., 2013; Alves et al., 2014).
BACE1 is a promising target gene because is responsible for
the cleavage of the amyloid precursor protein into amyloid-β
fragments, a crucial step for the initiation of amyloid pathology
(Peters et al., 2018). Lange et al. found an association of the
rs638405 polymorphism of BACE1 with increased risk of PD
in a Norwegian population (Lange et al., 2015). Furthermore,
another research group identified a potential link between
AD and MSA pathology, which involves the deregulation of
microRNAs (miRNAs) and BACE1 (Kim et al., 2019). Several
studies have identified minimally invasive biomarkers using
body fluids such as serum, blood, plasma, urine and saliva.
miRNAs are a class of endogenous RNAs, which regulate gene
expression at post-transcriptional level (Ramaswamy et al., 2018).
Many studies suggest that miRNAs can cross the blood brain
barrier and enter body fluids such as blood (Kumar and Reddy,
2016). Circulating miRNAs (cmiRNAs) are highly stable, easily
quantifiable and accessible by minimally-invasive procedures.
Change in the expression of many cmiRNAs is associated with
pathophysiological processes relevant to PD pathology. Several
reports suggest the utility of cmiRNAs as potential biomarkers
for PD and other parkinsonian disorders (Ubhi et al., 2014;
Schafferer et al., 2016; Huang et al., 2019; Vallelunga et al., 2019).
Many miRNAs regulate the expression of BACE 1 but miR-339-
5p directly interacts with the 3′-UTR of BACE-1 and deregulates
its expression and biological activity (Rahmani et al., 2019). Long
et al. reported that miR-339-5p regulates BACE-1 in human brain
cells and it is dysregulated in a subset of AD patients (Long
et al., 2014). In a previous study, we found a decrease of serum
miR-339-5p in 25 MSA and 25 PD patients compared with 25
healthy controls (HC) (Vallelunga et al., 2014b). MiR-96-5p has
also shown promise as a potential biomarker. Ubhi et al. reported
an increase of miR-96 in human brain MSA samples and in a
mouse model of MSA (Ubhi et al., 2010). Furthermore, they
observed that target genes of miR-96-5p were decreased in MSA
patients and a mouse model of MSA (Virachit et al., 2019). In
addition, Schafferer et al. found an increase of miR-96 in the later
stages ofMSA in both themousemodel and humanMSA samples
(Schafferer et al., 2016). Recently, Vidal-Martinez et al. reported
that FTY720-Mitoxy, a FTY720-derivative known to increase
expression of oligodendrocyte brain-derived neurotrophic factor
(BDNF), glial cell line-derived neurotrophic factor (GDNF), and
nerve growth factor (NGF), reduces brain miR-96-5p (Vidal-
Martinez et al., 2020). In the present study, our primary aim was
to investigate serum levels of miR-339-5p and miR-96-5p from
MSA and PD patients compared to HC. Our secondary aim was
to assess whether miR-339-5p and miR-96-5p expression could
differentiate PD fromMSA patients.
METHODS
Study Design and miRNAs Quantification
In a previous study (Vallelunga et al., 2014b), we detected
differences between selected miRNAs between MSA and PD
patients using a sample of 25 patients in each group. Based on
the findings from our previous investigation, in the present study,
we recruited 51 PD and 52 MSA patients diagnosed according
to the criteria currently used in the clinic (Gilman et al., 2008;
Postuma et al., 2015). We included 56 HC with no history of
neurological or psychiatric diseases. Serum samples from PD and
MSA patients were collected at the Center for Neurodegenerative
Diseases at the University of Salerno (Salerno, Italy), and the
Department of Neurology at the Expert Center for PD and
French Reference Center for MSA at the University Hospital of
Bordeaux (Bordeaux, France). Serum samples fromHCwere also
collected at the institutions mentioned above. The study protocol
was approved by the institutional review board at the University
of Salerno (Salerno, Italy) and the CPP Sud-Ouest et Outre-Mer
III (Bordeaux, France). Informed consent was obtained from
all participants. Demographic and clinical features are reported
in the Supplementary Table 1. Blood samples were obtained
by vein puncture using dry vacutainer tubes (BD Biosciences,
Italy). Each sample was processed for serum isolation within
2 h after withdrawal according to the protocol described below.
Whole blood was left to stand for about 30min at 20◦C before
being centrifuged at 3,000 rpm for 15min at 4◦C. The serum
was divided into aliquots and stored at −80◦C until analysis.
Before analyzing the serum samples, we assessed hemolysis
according to Shah et al. (2016), which determined the ratio
of miR-451a (ID: 001105; Thermo Fisher Scientific, Italy) to
miR-23a-3p (ID: 0003999; Thermo Fisher Scientific, Italy) to
determine the samples with low (miR ratio < 5), moderate (5
< miR ratio > 7) and severe (miR > 7) grade of hemolysis.
We then proceeded to exclude all samples with moderate
or severe hemolysis. Serum miR-339-5p and miR-96-5p were
quantified using LNATM enhanced microRNA assay (Exiqon)
according to our previous published protocol (Vallelunga et al.,
2019). Each miRNA was quantified in duplicate and mean Ct
values were used for fold change calculations. The identification
numbers of miRNA assays (probes) used for RT-qPCR are as
follows: has-miR-93-5p (204715), has-miR-339-5p (206007) and
has-miR-96-5p (204417).
Data Analysis and Statistics
We normalized the data using miR-93-5p as reference miRNA
(Vallelunga et al., 2019). To establish if miR-93-5p was an
appropriate normalizer, we analyzed miR-93-5p in our cohorts
of patients and HCs. This data was normally distributed as
assessed by D’Agostino and Pearson test and was analyzed
using a one-way analysis of variance (ANOVA), which showed
no difference among PD, MSA and HC subjects divided by
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FIGURE 1 | Comparison of 2−1CT values for serum miR-96-5p between MSA and HC (A), PD and HC (B), and PD and MSA (C) subjects. **p < 0.01 and
****p < 0.0001.
sex (Supplementary Figure 1). We considered 37 as a cut off
value for Cts and we excluded samples with Ct values higher
than 37 from the analysis. We calculated the fold changes (fc)
using the 2−1CT method for miR-339-5p and miR-96-5p. These
data were not normally distributed as assessed by D’Agostino
and Pearson test and were analyzed using a Mann-Whitney
test for comparison of miRNA expression levels among PD,
MSA and HC groups. Correlations between miRNA expression
and disease duration were assessed using the Spearman’s
correlation test. To assess the diagnostic accuracy of miRNAs
to discriminate among PD and MSA patients, we performed
a receiver operating characteristic curve (ROC). All statistical
analyses were performed using GraphPad Prism (GraphPad
Software Inc., San Diego, CA, USA) except for the ROC analyses,
which were performed using MedCalc Software Version 19.6.4
(Ostend, Belgium). A p < 0.05 was considered significant.
Target Prediction
Target prediction of miR-96-5p and miR-339-5p was
obtained querying the microRNA-target interactions using
the miRTarBase, chosen due to its widespread use and
completeness. We considered only strong mRNA-miRNA
interactions experimentally confirmed by qRT-PCR, luciferase
assays and Western Blots. Then, we used the search tool for
retrieval of interacting genes (STRING) to evaluate co-expression
relationships among target genes. We considered only the target
genes with co-expression coefficients >0.7.
RESULTS
Serum miR-96-5p
We observed that miR-96-5p was significantly increased in MSA
(Mean± SEM:0.096± 0.048) patients compared with HC (Mean
± SEM:0.057± 0.009) (fc: 1.61; p < 0.0001) (Figure 1A).
We performed a ROC analysis to establish the diagnostic
accuracy of miR-96-5p and we observed that this miRNA
discriminated well between MSA and HC [area under the
curve (AUC) = 0.736; p < 0.001] with a sensitivity of
77.4% and a specificity of 67.3% (Supplementary Figure 2).
Similarly, miR-96-5p expression was decreased in PD patients
(Mean ± SEM:0.051 ± 0.012) compared with HC (Mean
± SEM:0.057 ± 0.009) (fc:0.89; p < 0.01) (Figure 1B). The
AUC for miR-96-5p, when comparing PD and HC, was
0.645 (Supplementary Figure 3). We did not observe significant
differences in miR-96-5p levels when comparing PD and MSA
patients (fc:1.1; p = 0.74) (Figure 1C). When analyzing male
and female miR-96-5p data separately, we found an increase
of miR-96-5p in female MSA patients (fc:1.62; p < 0.05)
(Supplementary Figure 4A) and male counterparts (Mean ±
SEM:0.085 ± 0.067) (fc:1.65; p < 0.001) (Figure 2A) compared
with HC female and male subjects (Mean ± SEM:0.05 ± 0.008),
respectively. Furthermore, we observed a significant miR-96-
5p increase only when comparing male PD subjects (Mean
± SEM:0.058 ± 0.02) to sex-matched HC subjects (Mean ±
SEM:0.05 ± 0.08) (fc:1.17; p < 0.05) (Figure 2B). No significant
differences were observed when comparing MSA and PD male
patients (Figure 2C). The results of the ROC analyses for
this miRNA are reported in the Supplementary Materials and
indicate that miR-96-5p is moderately accurate in the context of
our comparisons. Nevertheless, when comparing MSA and HC
male patients, we observed a high specificity (92%) and moderate
sensitivity (63%) (Supplementary Figures 5–7). No significant
differences were observed for miR-96-5p when comparing MSA-
P with MSA-C (Supplementary Figure 8B). No correlation was
found between miR-96-5p levels and disease duration in both PD
and MSA patients of both sexes (Supplementary Figures 9, 10).
Using miRTarBase, we identified 203 target genes of miR-96-5p
but only 27 of them had experimentally confirmed strongmRNA-
miRNA interactions. Many predicted target genes are involved
in neurodegeneration. By using STRING, we found several
interactions among target proteins (Supplementary Figure 11).
We observed that 12 target genes are involved in the regulation
of apoptotic processes [False Discovery Rate (FDR) = 2.66e-05].
In addition, 10 target genes are implicated in neurogenesis (FDR
= 0.00069) and seven genes are involved in the regulation of
neurogenesis (FDR = 0.0012). Other target genes are implicated
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FIGURE 2 | Comparison of 2−1CT values for serum miR-96-5p between male MSA and HC (A), PD and HC (B), and PD and MSA (C) subjects. *p < 0.05 and
***p < 0.001.
FIGURE 3 | Comparison of 2−1CT values for serum miR-339-5p between MSA and HC (A), PD and HC (B), and PD and MSA (C) subjects. ****p < 0.0001 and
**p < 0.01.
in the regulation of dopamine receptor signaling. These results
suggest that these genes work together in different pathways
involved in neurodegeneration such as neuronal survival and
dopaminergic signaling (Supplementary Table 2).
Serum miR-339-5p
We found an decrease of miR-339-5p in MSA patients (Mean ±
SEM:0.107 ± 0.049) compared with HC (Mean ± SEM:0.132 ±
0.021) (fc: 0.80; p < 0.0001) (Figure 3A).
Similarly, we observed a decrease of miR-339-5p in
MSA female (Mean ± SEM:0.154 ± 0.094) (fc:0.98; p <
0.0001) (Figure 4A) and male (fc:0.6; p < 0.001) patients
(Supplementary Figure 12A) compared with sex-matched HC
(Mean ± SEM:0.156 ± 0.033). No differences were observed in
PD patients compared with HC in regards to miR-339-5p for
both male and female patients (Figures 3B and 4B).
We observed a significant increase of miR-339-5p in PD
patients (Mean ± SEM:0.509 ± 0.105) compared with MSA
patients (Mean ± SEM:0.107 ± 0.049) (fc:4.78; p < 0.01)
(Figure 3C). To determine the diagnostic accuracy of miR-339-
5p to discriminate between PD and MSA, a ROC analysis
was performed. The specificity of miR339-5p to discriminate
between MSA and PD was 90.6% but the sensitivity was 51%
(Supplementary Figure 13). When analyzing male and female
miR data separately, we found a significant increase of miR-339-
5p only in PD female patients (Mean ± SEM:0.595 ± 0.160)
compared with MSA female subjects (Mean ± SEM:0.154 ±
0.094) (fc:3.84; p < 0.01) (Figure 4C). The specificity of miR339-
5p to discriminate between PD and MSA female subjects was
88%, and the sensitivity was 68.8% (Supplementary Figure 14).
A significant correlation was observed between disease duration
in female PD patients and mir-339-5p (r = −0.783; p
< 0.0001) (Supplementary Figure 9A) and disease duration
in male PD subjects and mir-339-5p (r = −0.773; p <
0.0001) (Supplementary Figure 9B). No significant differences
were observed for miR-339-5p when comparing MSA-P
with MSA-C (Supplementary Figure 8A). No correlation was
found between miR-339-5p and disease duration in both
female (Supplementary Figure 10A) and male MSA patients
(Supplementary Figure 10B). By using miRTarBase database,
we identified 237 target genes but only 5 of them showed
experimentally confirmed strong mRNA-miRNA interactions
(BACE1, NOVA1, MDM2, BCL6 and PTP4A1). Moreover,
we observed that other target genes with weak predicted
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FIGURE 4 | Comparison of 2−1CT values for serum miR-339-5p between female MSA and HC (A), PD and HC (B), and PD and MSA (C) subjects. ****p < 0.0001
and **p < 0.01.
functionality could be involved in the pathogenesis of MSA (i.e.,
AMBRA1, CTSD, ELOVL7 and HNRNPA1). No relationship
among target genes was identified.
DISCUSSION
In our study, we found a significant increase of serum miR-96-
5p in MSA patients compared to HC while in PD patients we
observed a decrease compared to HC. Our results are consistent
with the increasedmiR-96-5p expression in the transgenicmyelin
basic protein (MBP) mouse model of MSA and post-mortem
brain tissue from MSA patients (Ubhi et al., 2014; Schafferer
et al., 2016) while miR-96-5p has not previously been studied
in PD. Ubhi et al. found a decrease of miR-96 target genes
in human MSA brain and transgenic MBP mice pointing to a
possible involvement of this miRNA in MSA pathogenesis (Ubhi
et al., 2014). Recently, Schafferer et al. also observed that miR-
96-5p was increased in brain tissue from MSA patients but not
in the early pre-symptomatic stage in the transgenic proteolipid
protein mouse model of MSA (Schafferer et al., 2016). This
difference may be related to changes in the miRNA profile as
disease progresses, which may reflect different events in the
early and late stages of MSA. Recently, Vidal-Martinez et al.
observed that levels of miR-96-5p were significantly reduced
in FTY720-Mitoxy treated aSyn Tg mice that display MSA-
like impairments. Furthermore, they confirmed that FTY720-
Mitoxy increases neuronal BDNF and oligodendroglial GDNF,
BDNF and NGF expression. For the above reasons, FTY720-
Mitoxy could be a potential therapeutic agent for MSA that can
improve motor function while decreasing synucleinopathy. The
beneficial effects of this therapeutic agent were associated with
reduced miR-96-5p expression and a corresponding increase in
the neurotrophic factor GDNF (Vidal-Martinez et al., 2020).
Using miRTarBase, we predicted several target genes of miR-
96-5p and hypothesize that an increase of this miRNA can
lead to decrease of predicted target genes. We identified 203
target genes of miR-96-5p using miRTarBase and used STRING
to determine protein interactions among those genes involved
in key biological processes such as regulation of apoptosis,
dopaminergic signaling and neurogenesis. Many predicted target
genes are involved in neuronal survival and synaptic plasticity
and have a neuroprotective function such as BDNF, GDNF and
tissue inhibitor of metalloproteinases-1 (TIMP-1). Other target
genes may be specifically involved in the pathogenesis of MSA
such as SLC1A1 and SLC6A6 (Ubhi et al., 2010). Recently, Huang
et al. observed a significant reduction of BDNF expression in
peripheral blood lymphocytes of PD patients. In addition, they
found that BDNF levels were associated with disease duration,
Unified Parkinson’s Disease Rating Scale score, H-Y staging
and treatment with L-DOPA (Lorenzl et al., 2003). Rahmani
et al. conducted a meta-analysis to study if serum/CSF levels
of BDNF change in patients with PD. All studies considered
in this meta-analysis reported a significant reduction of BDNF
in PD patients’ CSF and serum compared to HC (Shi et al.,
2015). Recently, Virachit et al. observed a significant reduction
in hippocampal levels of GDNF in PD patients compared to
HC (Virachit et al., 2019). Ubhi et al. quantified GDNF levels
in several brain regions of MSA patients. They found a 50%
reduction in frontal cortex white matter and cerebellum of MSA
patients compared with HC (Ubhi et al., 2010). Conflicting
data were reported for TIMP-1 levels in PD patients. For
instance, Lorenz et al. found an increase of TIMP-1 levels in
CSF from PD patients (Lorenzl et al., 2003). On the contrary,
Shi et al. showed a reduced TIMP-1 concentration in CSF of
PD patients (Shi et al., 2015). Selective loss of SLC1A1 has
been implicated in the cerebellar form of MSA (Dirson et al.,
2002). Ubhi et al. observed a significant decrease in SLC1A1
mRNA in brain tissues from MSA patients and in transgenic
MBP mice (Ubhi et al., 2014). SLC6A6, a taurine transporter
with a neuroprotective role, was significantly reduced in MSA
patients’ frontal cortex (Ubhi et al., 2014). In the present study
we also observed a significant increase of miR-339-5p in MSA
compared to PD patients suggesting that it could represent a
potential biomarker to differentiate MSA from PD. In regards
to diagnostic accuracy of miR-339-5p to discriminate between
PD and MSA patients, it is worth noting that the ROC analysis
showed a high specificity (90.6%) to discriminate between MSA
and PD although the sensitivity was 51%. This high specificity
was also observed when analyzing female miR339-5p data (88%).
In this study, we confirm that miR-339-5p levels are lower in
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MSA vs. HC in line with our previous publication (Vallelunga
et al., 2014b). Additionally, no deregulation was observed in
either of the articles when comparing PD to controls. In the
current study, we observed an increase in miR-339-5p in PD
vs. MSA patients. This may be due to the increased number of
patients involved in the present study. In addition, the cohorts of
patients we enrolled in our two studies present different clinical
characteristics, which may also explain differences between the
findings from our two studies. We identified 237 targets of
miR-339-5 but only 5 genes showed a strong mRNA-miRNA
interaction (BACE1, NOVA1, MDM2, BCL6 and PTP4A1).
These are implicated in different neurodegenerative diseases.
Intriguingly, we found that some predicted genes with weak
functionality were involved in MSA pathogenesis including
AMBRA1 and Cathepsin D (CTDS). Miki et al. observed an
association between AMBRA1 and the native α-synuclein in
MSA patients’ brains. In addition, they found a decrease in
levels of native α-synuclein binding to AMBRA1 in the cerebral
cortex or cerebellar white matter of MSA patients compared with
HC (Miki et al., 2018). Recently, Kiely et al. (2019) observed
that CTDS activity was significantly increased in multiple brain
regions of MSA patients. Further studies in larger cohorts of
patients are necessary to confirm our findings and to take a step
toward a minimally-invasive biomarker-based diagnosis of MSA
and PD.
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